Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
Fennec Pharmaceuticals

Fennec Pharmaceuticals (NASDAQ: FENC) insider transactions

In the twelve months to 10 November 2026, executives and directors of Fennec Pharmaceuticals reported 18 open-market sales of 1,478,063 shares ($11.8m) and 0 open-market purchases, by 8 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Fennec Pharmaceuticals shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
31 October 2026Andrade RobertChief Financial OfficerGrant or award+1,703—248,558Form 4
31 October 2026Hackman Jeffrey S.Chief Executive OfficerGrant or award+1,159—70,844Form 4
31 October 2026Evans Terry LChief Commercial OfficerGrant or award+168—24,181Form 4
31 October 2026Sayad Pierre SargisChief Medical OfficerGrant or award+168—13,701Form 4
31 October 2026Cioffi Christiana MarieChief Strategy OfficerGrant or award+156—28,902Form 4
12 October 2026Andrade RobertChief Financial OfficerGrant or award+3,846$5.53246,855Form 4
12 October 2026Hackman Jeffrey S.Chief Executive OfficerGrant or award+2,224$5.5369,685Form 4
12 October 2026Evans Terry LChief Commercial OfficerGrant or award+2,326$5.5324,013Form 4
12 October 2026Sayad Pierre SargisChief Medical OfficerGrant or award+3,846$5.5313,533Form 4
12 October 2026Cioffi Christiana MarieChief Strategy OfficerGrant or award+3,946$5.5328,746Form 4
30 September 2026Andrade RobertChief Financial OfficerGrant or award+1,703—243,009Form 4
30 September 2026Hackman Jeffrey S.Chief Executive OfficerGrant or award+1,159—67,461Form 4
30 September 2026Evans Terry LChief Commercial OfficerGrant or award+168—21,687Form 4
30 September 2026Sayad Pierre SargisChief Medical OfficerGrant or award+168—9,687Form 4
30 September 2026Cioffi Christiana MarieChief Strategy OfficerGrant or award+156—24,800Form 4
15 September 2026Brughera Marco MariaDirectorOption exercise, 10b5-1 plan+15,545$2.1115,545Form 4
15 September 2026Brughera Marco MariaDirectorOpen-market sale, 10b5-1 plan−15,545$10.290Form 4
1 September 2026Raykov Rosty—Open-market sale, 10b5-1 plan−10,000$12.11124,411Form 4
31 August 2026Raykov Rosty—Grant or award, 10b5-1 plan+2,778—134,411Form 4
31 August 2026Andrade RobertChief Financial OfficerGrant or award+1,703—241,306Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Fennec Pharmaceuticals page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.